|
|
Mesa Laboratories Inc (NASDAQ: MLAB) |
|
Price: $127.7800
$-0.75
-0.584%
|
| Day's High:
| $128.2899932861328
| Week Perf:
| -0.07 %
|
| Day's Low: |
$ 125.59 |
30 Day Perf: |
26.5 % |
| Volume (M): |
100,553 |
52 Wk High: |
$ 132.70 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$89.88 |
| Open: |
$126.09 |
52 Wk Low: |
$58.83 |
|
|
| Market Capitalization (Millions $) |
736 |
| Shares
Outstanding (Millions) |
6 |
| Employees |
717 |
| Revenues (TTM) (Millions $) |
249 |
| Net Income (TTM) (Millions $) |
5 |
| Cash Flow (TTM) (Millions $) |
6 |
| Capital Exp. (TTM) (Millions $) |
3 |
Business Description
Mesa Laboratories, Inc. was incorporated under the laws of the State of Colorado
on March 26, 1982. We pursue a strategy of focusing primarily on quality control
products, which are sold into niche markets that are driven by regulatory requirements.
We prefer markets that have limited competition where we can establish a commanding
presence and achieve high gross margins. We are organized into three divisions
across six physical locations. Our Instruments Division designs, manufactures
and markets quality control instruments and disposable products utilized in
connection with the healthcare, pharmaceutical, food and beverage, medical device,
industrial hygiene, environmental air sampling and semiconductor industries.
Our Biological Indicators Division manufactures and markets biological indicators
and distributes chemical indicators used to assess the effectiveness of sterilization
processes, including steam, hydrogen peroxide, ethylene oxide and radiation,
in the hospital, dental, medical device and pharmaceutical industries. Our Continuous
Monitoring Division designs, develops and markets systems which are used to
monitor various environmental parameters such as temperature, humidity and differential
pressure to ensure that critical storage and processing conditions are maintained
in hospitals, pharmaceutical and medical device manufacturers, blood banks,
pharmacies and a number of other laboratory and industrial environments.
Our Lakewood, Colorado, and Butler, New Jersey, facilities manufacture our
Instruments Division products which include the DataTrace®, DialyGuard®,
DryCal®, Torqo®, SureTorque® and BGI brands. Our Omaha, Nebraska,
and Bozeman, Montana locations manufacture our Biological Indicators Division
products which include the Mesa, PCD® and Apex® brands, while our Lakewood,
Colorado, facility also manufactures our Continuous Monitoring Division products
which include CheckPoint® and AmegaView brands.
Our philosophy is to manufacture exceptional quality products and provide a
high level of on-going service for those products. Our revenues come from two
main sources – product sales and services. Our strategic goals involve
continuing to grow revenues and profits through three key strategies –
a) improving our distribution channels, b) introducing new products to the market,
and c) seeking out companies or product lines to acquire.
Product sales are dependent on several factors, including general economic
conditions, both domestic and international, customer capital spending trends,
competition, introduction of new products and acquisitions. Biological indicator
products are disposable and are used on a routine basis for quality control,
thus product sales are less sensitive to general economic conditions. Instrument
products and continuous monitoring systems have a longer life, and their purchase
by our customers is somewhat discretionary, so sales are more sensitive to general
economic conditions. Service demand is driven by our customers’ quality
control and regulatory environments, which require periodic repair and recalibration
or certification of our instrument products and continuous monitoring systems.
We typically evaluate costs and pricing annually. Our policy is to price our
products competitively and, where possible, we try to pass along cost increases
in order to maintain our margins.
Company Address: 12100 West Sixth Avenue Lakewood 80228 CO
Company Phone Number: 987-8000 Stock Exchange / Ticker: NASDAQ MLAB
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Announcement
Published Mon, Apr 7 2025 7:35 PM UTC
Mesa Laboratories Declares Quarterly Dividend, Reflects Commitment to Shareholder Value LAKEWOOD, Colo. April 7, 2025 Mesa Laboratories, Inc. (NASDAQ: MLAB) has announced its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. This dividend is set to be paid on June 16, 2025, to shareholders who are on record as of the close o...
|
| Announcement
Published Mon, Jul 8 2024 6:00 PM UTC
Mesa Laboratories, Inc. recently made an exciting announcement, declaring a regular quarterly dividend of $0.16 per share for its common stock. This news reflects the company s commitment to providing value to its shareholders and its confidence in its financial performance.The dividend payout is set to be made on September 16, 2024, to the shareholders of record as of Augus...
|
| Announcement
Published Fri, May 31 2024 10:00 AM UTC
Mesa Laboratories, Inc. (Mesa) (NASDAQ:MLAB), a leading global provider of quality control solutions, has announced a delay in the release of its unaudited fourth-quarter and full fiscal year 2024 financial results. The delay is due to ongoing efforts by the company to finalize its year-end audit, which is primarily focused on completing the calculations and technical accoun...
|
| Announcement
Published Wed, May 22 2024 10:00 AM UTC
Mesa Laboratories, Inc. Revises Earnings Announcement and Releases Second Annual Responsible Business Program BrochureMesa Laboratories, Inc., a global leader in life science tools and critical quality control solutions, has recently announced two significant updates. The company has revised the earnings announcement date for its unaudited fourth quarter and full fiscal year...
|
| Announcement
Published Mon, Apr 1 2024 2:27 PM UTC
Mesa Laboratories, Inc. to Announce Unaudited Fourth Quarter and Full Fiscal Year 2024 Results on May 24, 2024LAKEWOOD, Colo., April 01, 2024 - Mesa Laboratories, Inc., a leading global provider of critical quality control solutions for various industries, including pharmaceuticals, medical devices, and food and beverage, has announced that it will be releasing its financial...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
0.85 $ |
| Revenues (TTM) |
43.33 $
|
| Cash Flow (TTM) |
0.98 $ |
| Cash |
5.6 $
|
| Book Value |
32.79 $
|
| Dividend (TTM) |
0.64 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
347,934 |
| Net
Income per Employee (TTM) |
6,695 |
| Receivable Turnover Ratio (TTM) |
6.21 |
| Inventory Turnover Ratio (TTM) |
3.34 |
| Asset Turnover Ratio (TTM) |
0.58 |
|
|
| Per Share |
|
| Earnings (TTM) |
0.85 $
|
| Revenues (TTM) |
43.33 $ |
| Cash Flow (TTM) |
0.98 $ |
| Cash |
5.6 $
|
| Book Value |
32.79 $ |
| Dividend (TTM) |
0.64 $ |
|
|
| |
| Sterilization and Disinfection Control |
|
40.75 % |
of total Revenue |
| Biopharmaceutical Development |
|
20.05 % |
of total Revenue |
| Calibration Solutions |
|
22.09 % |
of total Revenue |
| Clinical Genomics |
|
17.11 % |
of total Revenue |
| Consumables |
|
57.83 % |
of total Revenue |
| Hardware and Software |
|
23.49 % |
of total Revenue |
| Service |
|
18.68 % |
of total Revenue |
| US |
|
49.46 % |
of total Revenue |
| CN |
|
9.04 % |
of total Revenue |
| Other |
|
41.5 % |
of total Revenue |
| Corporate Non Segment |
|
100 % |
of total Revenue |
|
|